111, Inc. (YI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
111, Inc. (YI) trades at $3.99 with AI Score 44/100 (Grade C). 111, Inc. operates an integrated online and offline healthcare platform in China, focusing on both B2B and B2C segments. Market cap: $34.9M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: May 9, 2026Analyst Coverage for YI: YI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates YI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
YI: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
111, Inc. (YI) Healthcare & Pipeline Overview
111, Inc. (YI) is an integrated online and offline healthcare platform in China, providing pharmaceuticals, wellness products, and healthcare services. Operating through B2B and B2C segments, the company distinguishes itself through its comprehensive supply chain integration and online marketplace, serving pharmacies, pharmaceutical companies, and consumers.
What Is the Investment Thesis for YI?
111, Inc. presents a unique investment opportunity within China's rapidly evolving healthcare market. The company's integrated online and offline platform caters to both businesses and consumers, creating multiple revenue streams. With a market capitalization of $34.9M, the company is positioned to capitalize on the increasing demand for healthcare products and services in China. Key growth catalysts include expanding its online marketplace and further integrating its supply chain. However, the company's negative profit margin of -0.4% and the competitive landscape pose significant risks. The company's beta of 0.70 suggests lower volatility compared to the overall market. Investors should monitor the company's ability to improve profitability and navigate regulatory challenges.
Based on FMP financials and quantitative analysis
YI Key Highlights
- Operates an integrated online and offline healthcare platform in China, providing access to a broad range of pharmaceutical and wellness products.
- B2B segment focuses on supplying products and services to pharmacies, pharmaceutical companies, and distributors, creating a diversified revenue stream.
- B2C segment offers direct sales to consumers through online retail and offline pharmacies, enhancing market reach.
- Operates an online marketplace facilitating transactions between third-party sellers and pharmacies, expanding product offerings and revenue opportunities.
- Gross margin of 5.8% indicates potential for improvement through supply chain optimization and pricing strategies.
Who Are YI's Competitors?
YI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JD JD.com, Inc. | $30.09 | -0.20% | $40.6B | 44 |
| PDD PDD Holdings Inc. | $83.30 | -0.35% | $119B | 58 |
| MYCOF Noveris Health Sciences Inc. | $0.80 | -3.73% | $46.8M | 48 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.3M | 63 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $115M | 50 |
| HITI High Tide Inc. | $2.15 | -0.23% | $188M | 47 |
| HEWA HealthWarehouse.com, Inc. | $0.12 | +0.00% | $5.12M | 55 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $0.65 | +0.00% | $543M | 55 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are YI's Key Strengths?
- Integrated online and offline platform.
- Comprehensive product offerings.
- Strong supply chain integration.
- Established brand name in China.
What Are YI's Weaknesses?
- Negative profit margin.
- Limited geographic presence outside of major cities.
- Reliance on third-party sellers for marketplace revenue.
- Exposure to regulatory changes in China.
What Could Drive YI Stock Higher?
- Expansion of the online marketplace by attracting more third-party sellers and increasing product offerings.
- Further integration of the supply chain to improve efficiency and reduce costs.
- Potential strategic partnerships with pharmaceutical companies to gain access to exclusive products and marketing support.
- Geographic expansion within China by opening new retail pharmacies and expanding online reach.
What Are the Key Risks for YI?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from other online pharmacies and distributors in China.
- Regulatory changes affecting the pharmaceutical industry in China.
- Economic slowdown in China impacting consumer spending on healthcare products.
- Fluctuations in currency exchange rates affecting the value of the ADR.
What Are the Growth Opportunities for YI?
- Expansion of Online Marketplace: 111, Inc. can significantly expand its online marketplace by attracting more third-party sellers and increasing the range of products offered. The online marketplace model allows for scalability and diversification of revenue streams. The market for online pharmaceutical sales in China is projected to reach $50 billion by 2028, presenting a substantial growth opportunity for 111, Inc.
- Further Integration of Supply Chain: Integrating its supply chain can improve efficiency, reduce costs, and enhance the company's competitive position. By streamlining procurement, logistics, and warehousing, 111, Inc. can improve its gross margin and offer more competitive pricing. Investing in advanced supply chain technologies and building strategic partnerships with suppliers can drive this growth.
- Expansion of Value-Added Services: 111, Inc. can expand its value-added services, such as online consultations and electronic prescription services, to attract more customers and generate additional revenue. The market for online healthcare services in China is growing rapidly, driven by increasing demand for convenient and accessible healthcare solutions. By offering a comprehensive suite of services, 111, Inc. can differentiate itself from competitors.
- Strategic Partnerships with Pharmaceutical Companies: Forming strategic partnerships with pharmaceutical companies can provide 111, Inc. with access to exclusive products and marketing support. These partnerships can also help the company expand its product offerings and reach new customer segments. Collaborating with leading pharmaceutical companies can enhance 111, Inc.'s credibility and market position.
- Geographic Expansion within China: 111, Inc. can expand its geographic presence within China by opening new retail pharmacies and expanding its online reach to underserved regions. The Chinese healthcare market is vast and diverse, with significant opportunities for growth in Tier 2 and Tier 3 cities. By targeting these markets, 111, Inc. can increase its customer base and revenue.
What Opportunities Does YI Have?
- Expansion of online marketplace.
- Further integration of supply chain.
- Strategic partnerships with pharmaceutical companies.
- Geographic expansion within China.
What Threats Does YI Face?
- Intense competition from other online pharmacies and distributors.
- Regulatory changes affecting the pharmaceutical industry.
- Economic slowdown in China.
- Fluctuations in currency exchange rates.
What Are YI's Competitive Advantages?
- Integrated Platform: Combines online and offline channels to reach a broad customer base.
- Supply Chain Integration: Streamlines procurement, logistics, and warehousing to improve efficiency.
- Online Marketplace: Provides a platform for third-party sellers to reach pharmacies, expanding product offerings.
- Value-Added Services: Offers online consultations and electronic prescription services to attract and retain customers.
What Does YI Do?
Founded in 2010 and headquartered in Shanghai, China, 111, Inc. (YI), formerly known as New Peak Group, has evolved into a comprehensive healthcare platform. The company operates through two primary segments: B2B and B2C. Its B2C operations involve selling medical and wellness products directly to consumers through online retail and its own retail pharmacies under the Yi Hao Pharmacy brand. The B2B segment focuses on supplying products and services to pharmacies, pharmaceutical companies, and distributors. 111, Inc. offers a wide array of products, including prescription and over-the-counter drugs, nutritional supplements, contact lenses, medical supplies, personal care products, and baby products. Beyond product sales, 111, Inc. provides value-added services such as online consultations and electronic prescription services. The company also operates an online marketplace, enabling third-party sellers to reach pharmacies directly. Additionally, 111, Inc. offers supply chain integration, data services, warehousing, logistics, procurement, research and development, and IT support. As of December 31, 2021, 111, Inc. operated 14 offline retail pharmacies across several Chinese provinces.
What Products and Services Does YI Offer?
- Operates an integrated online and offline healthcare platform in China.
- Sells medical and wellness products through online retail and wholesale channels.
- Provides value-added services such as online consultations and electronic prescriptions.
- Operates retail pharmacies under the Yi Hao Pharmacy brand.
- Offers an online marketplace for third-party sellers to reach pharmacies.
- Provides supply chain integration and data services to pharmacies and pharmaceutical companies.
How Does YI Make Money?
- B2C: Sells medical and wellness products directly to consumers through online retail and retail pharmacies.
- B2B: Supplies products and services to pharmacies, pharmaceutical companies, and distributors.
- Marketplace: Generates revenue from transaction fees on its online marketplace.
- Value-Added Services: Charges fees for online consultations and electronic prescription services.
What Industry Does YI Operate In?
111, Inc. operates within China's dynamic healthcare market, which is experiencing rapid growth driven by increasing healthcare spending and an aging population. The market is characterized by a mix of online and offline players, with a growing emphasis on digital healthcare solutions. 111, Inc. competes with other online pharmacies and traditional pharmaceutical distributors. The company's integrated platform and focus on supply chain integration provide a competitive edge. The Chinese government's support for digital healthcare initiatives also presents opportunities for growth.
Who Are YI's Key Customers?
- Consumers seeking medical and wellness products.
- Pharmacies requiring pharmaceutical supplies and services.
- Pharmaceutical companies seeking distribution channels.
- Distributors requiring supply chain integration and data services.
How 111, Inc. Is Valued
111, Inc. carries a market capitalization of $34.9M, placing it in the micro-cap category. Relative to its peer group, YI's quantitative score of 44/100 is roughly in line with the peer average of 53/100.
ROE 14%Key Financial Metrics
Return on equity for 111, Inc. stands at 13.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -26.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -38.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -31.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
111, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 38.02 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project 111, Inc. revenue of about $17.73B for fiscal 2026, with EPS near $0.00.
YI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in its long-term potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative strategies in the e-commerce sector.
- Market perception is improving as analysts recognize the company's efforts to expand its product offerings and enhance customer experience.
- Recent partnerships have been well-received, suggesting that 111, Inc. is positioning itself effectively within the competitive landscape.
Bear Case
- Concerns about the overall economic environment may dampen investor enthusiasm, as macroeconomic factors can impact consumer spending.
- Social sentiment has shown skepticism regarding the company's ability to sustain growth amid increasing competition in the e-commerce space.
- Some community members express doubts about the scalability of 111, Inc.'s operations, which could hinder future profitability.
- Recent reports indicate potential regulatory challenges that could affect the company's business model and operational flexibility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
YI Latest News
-
Stocks That Hit 52-Week Lows Of Monday
· Aug 12, 2019
YI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for YI.
Price Targets
Wall Street price target analysis for YI.
YI MoonshotScore
What does this score mean?
The MoonshotScore rates YI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Junling Liu
CEO
Junling Liu is the CEO of 111, Inc., bringing extensive experience in the healthcare and technology sectors. His background includes leadership roles at major multinational corporations, focusing on strategic planning, business development, and operational efficiency. He holds advanced degrees in business and technology, providing him with a strong foundation for leading a company at the intersection of healthcare and e-commerce. His expertise is crucial for navigating the complex Chinese market and driving the company's growth strategy.
Track Record: Under Junling Liu's leadership, 111, Inc. has focused on expanding its online marketplace and strengthening its supply chain integration. Key milestones include increasing the number of third-party sellers on the platform and improving the efficiency of its logistics operations. He has also overseen the expansion of the company's value-added services, such as online consultations and electronic prescription services.
111, Inc. ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company's stock that trades on U.S. stock exchanges. For 111, Inc. (YI), each ADR represents a certain number of ordinary shares traded on the company's home exchange. This allows U.S. investors to invest in YI without dealing with cross-border transactions or foreign currency conversions directly.
- Home Market Ticker: Shanghai, China
- ADR Level: 2
- ADR Ratio: 1:1
YI Healthcare Stock FAQ
What does the AI Score mean for YI?
YI holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. 111, Inc. operates an integrated online and offline healthcare platform in China, focusing on both B2B and B2C segments. They offer pharmaceuticals, wellness products, and healthcare services …
What does 111, Inc. do?
111, Inc. operates an integrated online and offline healthcare platform in China, focusing on both B2B and B2C segments. The company sells medical and wellness products through online retail and wholesale channels, as well as provides value-added services such as online consultations and electronic prescriptions. 111, Inc.
What do analysts say about YI stock?
Analyst coverage of YI stock is limited, reflecting its smaller market capitalization and focus on the Chinese market. Current consensus suggests a neutral outlook, with analysts citing the company's growth potential in the online healthcare market offset by concerns about profitability and competition. Key valuation metrics include price-to-sales ratio and enterprise value-to-revenue multiple. Investors should closely monitor the company's ability to improve its financial performance and execute its growth strategy.
What are the main risks for YI?
The main risks for 111, Inc. include intense competition from other online pharmacies and distributors in China, regulatory changes affecting the pharmaceutical industry, and the potential for an economic slowdown in China impacting consumer spending on healthcare products. Additionally, fluctuations in currency exchange rates can affect the value of the ADR.
What are the key factors to evaluate for YI?
111, Inc. (YI) holds an AI score of 44/100 (low). Not financial advice.
How frequently does YI data refresh on this page?
YI's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven YI's recent stock price performance?
111, Inc. (YI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated online and offline platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider YI overvalued or undervalued right now?
111, Inc. (YI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research YI before investing?
Before investing in 111, Inc. (YI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage may affect the accuracy of consensus estimates.
- Currency fluctuations can impact the value of the ADR.
- Regulatory changes in China can significantly affect the company's operations.